Tirzepatide: a new low for bodyweight and blood glucose The Lancet Diabetes & Endocrinology Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question The Obesity Wars of 2026 continue: Novo's Miss, Lilly's Supremacy, and the Quality of Weight Loss Pivot Semaglutide, Tirzepatide, Retatrutide and Cagrilintide are often lumped together, but they are not doing the same thing. : r Wegovy Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results